Table 1.
Demographic and array parameters for all subjects.
| Schizophrenics Short DOI: | Short Controls: | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGE | DOI | SEX | pH | PMI | 3′/5′ | %P | Drugs | Drug dose* | AGE | SEX | pH | PMI | 3′/5′ | %P | ||
| S1 | 38 | 4 | M | 6.02 | 50 | 1.25 | 31.8 | Haloperidol, Clozapine | 50 mg | Sc1 | 38 | M | 6.42 | 46 | 1.24 | 33.8 |
| S2 | 26 | 2 | M | 6.39 | 52 | 2.3 | 30.2 | Haloperidol | 500 mg | Sc2 | 26 | M | 6.42 | 24 | 1.17 | 29.9 |
| S3 | 19 | 3 | M | 6.22 | 43 | 1.27 | 32 | Haloperidol, Risperidone | 750 mg | Sc3 | 21 | M | 5.82 | 40 | 1.03 | 31.5 |
| S4 | 22 | 3 | M | 6.17 | 37 | 1.48 | 31.8 | Pimozide | 200 mg | Sc4 | 22 | M | 6.39 | 62 | 1.12 | 32.4 |
| S5 | 22 | 3 | M | 6.07 | 37 | 1.29 | 29.2 | Trifluoperazine, Flupenthixol | 450 mg | Sc5 | 25 | M | 6.48 | 50 | 1.19 | 32.4 |
| S6 | 25 | 2 | M | 6.38 | 49 | 1.1 | 31.9 | Trifluoperazine | 200 mg | Sc6 | 25 | M | 6.15 | 35 | 1.2 | 32.6 |
| S7 | 21 | 2 | F | 6.24 | 56 | 2.45 | 23.3 | Haloperidol | NA | Sc7 | 21 | F | 6.03 | 58 | 1.55 | 30.4 |
| S8 | 36 | 4 | F | 6.28 | 45 | 1.12 | 31.9 | Haloperidol | 160 mg | Sc8 | 38 | F | 6.14 | 50 | 1.19 | 31.4 |
| AVG = 330 ± 92.68 | ||||||||||||||||
| Schizophrenics Intermediate DOI: | Intermediate Controls: | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | DOI | Sex | pH | PMI | 3′/5′ | %P | Drugs | Drug dose* | Age | Sex | pH | PMI | 3′/5′ | %P | ||
| Int1 | 53 | 7 | M | 6.23 | 25 | 1.35 | 27.8 | Cholorpromazine | 200 mg | Ic1 | 53 | M | 6.43 | 12 | 1.23 | 30.6 |
| Int2 | 38 | 11 | M | 6.44 | 36 | 1.28 | 28 | Fluphenazine | 200 mg | Ic2 | 38 | M | 6.19 | 44 | 1.2 | 27.3 |
| Int3 | 41 | 11 | M | 6.2 | 31 | 1.13 | 29.5 | Fluphenazine | 500 mg | Ic3 | 42 | M | 6.21 | 26 | 1.08 | 32 |
| Int4 | 26 | 11 | F | 6.11 | 41 | 1.3 | 28.6 | Remoxipride | 750 mg | Ic4 | 29 | F | 6.38 | 34 | 1.19 | 30.1 |
| Int5 | 36 | 12 | M | 6.04 | 38 | 2.15 | 27.3 | Fluphenazine | 200 mg | Ic5 | 36 | M | 6.46 | 42 | 1.26 | 29.2 |
| Int6 | 45 | 12 | M | 6.33 | 68 | 1.09 | 31.6 | Stelazine | 300 mg | Ic6 | 48 | M | 6 | 52 | 1.3 | 29.2 |
| Int7 | 42 | 15 | M | 6.26 | 34.5 | 1.13 | 32.9 | Haloperidol | 670 mg | Ic7 | 44 | M | 6.38 | 44 | 1.34 | 27.7 |
| Int8 | 32 | 15 | M | 6.05 | 17 | 1.2 | 32.7 | Fluphenthixol | 610 mg | Ic8 | 34 | M | 6.46 | 15.5 | 1.24 | 31.5 |
| Int9 | 41 | 15 | M | 6.64 | 52 | 1.22 | 31.1 | Fluphenazine | 25 mg | Ic9 | 42 | M | 6.34 | 63 | 1.23 | 30.7 |
| int10 | 33 | 14 | M | 6.54 | 36 | 1.21 | 30.5 | None | Ic10 | 37 | M | 6.4 | 47 | 1.06 | 32.1 | |
| Int11 | 65 | 18 | F | 6.35 | 50 | 1.38 | 28.2 | Fluphenazine, Haloperidol | 550 mg | Ic11 | 66 | F | 6.37 | 43 | 1.33 | 30.5 |
| AVG = 400.5 ± 77.6 | ||||||||||||||||
| Schizophrenics Long DOI: | Long Controls: | |||||||||||||||
| AGE | DOI | SEX | pH | PMI | 3′/5′ | %P | Drugs | Drug dose* | AGE | SEX | pH | PMI | 3′/5′ | %P | ||
| L1 | 57 | 28 | M | 6.06 | 24 | 1.22 | 31.2 | Fluphenazine | 150 mg | Lc1 | 57 | M | 6.43 | 27 | 1.19 | 28.8 |
| L2 | 65 | 35 | M | 6.57 | 41 | 1.36 | 31.4 | Fluphenazine | 150 mg | Lc2 | 68 | M | 6.06 | 41 | 1.34 | 31.8 |
| L3 | 65 | 36 | M | 6.29 | 42 | 1.23 | 30.5 | Trifluphenazine, Haloperidol | 460 mg | Lc3 | 65 | M | 6.47 | 20.5 | 1.19 | 31.2 |
| L4 | 55 | 33 | M | 6.1 | 25 | 1.14 | 32.7 | Thioridazine | 400 mg | Lc4 | 50 | M | 6.43 | 69 | 1.38 | 30.2 |
| L5 | 61 | 38 | M | 6.46 | 37.5 | 1.19 | 29 | Fluphenazine | 745 mg | Lc5 | 60 | M | 6.11 | 27.5 | 1.05 | 30.4 |
| L6 | 71 | 53 | M | 6.45 | 48 | 1.35 | 30.3 | Thioridazine | 150 mg | Lc6 | 72 | M | 6.21 | 39 | 1.65 | 29.6 |
| L7 | 81 | 40 | F | 6.31 | 25 | 1.11 | 30.1 | Trifluphenazine | 100 mg | Lc7 | 80 | F | 6.28 | 55 | 1.54 | 30.6 |
| L8 | 67 | 36 | M | 6.46 | 21 | 1.15 | 33.9 | Fluphenazine | 75 mg | Lc8 | 65 | M | 6.56 | 41 | 1.24 | 30.7 |
| AVG = 278.8 ± 83.2 | ||||||||||||||||
*
Chlorpromazine equivalents; DOI, duration of illness; PMI, post-mortem interval; 3′/5′, GAPDH 3′/5′ ratio; %P, percent Present call. The average (AVG) cumulative drug doses ± S.E.M. for each schizophrenic cohort are shown.